Compare Repligen Corporation Common Stock (RGEN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vanguard Short Term Corporate Bond ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 4.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vanguard Short Term Corporate Bond ETF for 54 Days on average.
| RGEN | VCSH | |
|---|---|---|
Market Cap | $11.14B | $51.90B |
Volume | 1,259,263 | 4,498,428 |
Sector | Health | Fixed Income |
52-Week High | $194.57 | $80.20 |
52-Week Low | $102.87 | $77.03 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VCSH trades at $77.32, down 0.05% with a bearish technical signal. The ETF offers a competitive yield around 4.5% with a short 2.7-year duration, providing stability amid rising rates. Recent news highlights VCSH's lower expense ratio of 0.03% compared to peers and its focus on investment-grade corporate bonds. However, technical indicators show selling pressure with RSI at overbought levels and bearish moving average signals.
The outlook remains cautious due to tight credit spreads and limited price appreciation potential. While VCSH provides higher yield than treasury alternatives, it carries greater credit risk. Recent institutional activity shows mixed sentiment with both position increases and decreases reported. The ETF's short duration minimizes interest rate risk but faces headwinds from compressed spreads and competitive pressure from broader bond ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
